Expert Interview
Looking at the results from Anavex Life Sciences' Phase IIb/III Trial of Blarcamesine in Alzheimer's Disease
Ticker(s): AVXL, LLY, BIIBInstitution: University of Kansas
- Director of NIH-funded University of Kansas Alzheimer's Disease Center.
- Currently manages 300 patients with Alzheimer's disease.
- Research is focused on brain energy metabolism, the role brain energy metabolism plays in Alzheimer's Disease, and how to manipulate brain energy metabolism.
Please describe your background and practice setting
Added By: ben_adminExplain how your standard of care has evolved since the FDA approval of Leqembi and Kisunla
Added By: ben_adminWhat is your high level opinion on the data to date on Blarcamesine?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
